scholarly journals Stability of plasma amyloid‐β 1‐40, amyloid‐β 1‐42 and total Tau protein over repeated freeze/thaw cycles

2021 ◽  
Vol 17 (S5) ◽  
Author(s):  
Shieh‐Yueh Yang ◽  
H.C. Liu ◽  
Chin‐Hsien Lin ◽  
Ming‐Jang Chiu
Keyword(s):  
Tau Protein ◽  
Amyloid Β ◽  
Freeze Thaw ◽  
Total Tau

scholarly journals Stability of Plasma Amyloid-β 1–40, Amyloid-β 1–42, and Total Tau Protein over Repeated Freeze/Thaw Cycles

2020 ◽  
Vol 10 (1) ◽  
pp. 46-55
Author(s):  
Huei-Chun Liu ◽  
Ming-Jang Chiu ◽  
Chin-Hsien Lin ◽  
Shieh-Yueh Yang
Keyword(s):  
Tau Protein ◽  
Statistical Significance ◽  
Amyloid Β ◽  
Freeze Thaw ◽  
Total Tau ◽  
Thaw Cycle ◽  
Freeze Thaw Cycle ◽  
Fresh Plasma ◽  
The Stability ◽  
T Tau

Introduction: Blood biomarkers of Alzheimer’s disease (AD) have attracted much attention of researchers in recent years. In clinical studies, repeated freeze/thaw cycles often occur and may influence the stability of biomarkers. This study aims to investigate the stability of amyloid-β 1–40 (Aβ1–40), amyloid-β 1–42 (Aβ1–42), and total tau protein (T-tau) in plasma over freeze/thaw cycles. Methods: Plasma samples from healthy controls (n = 2), AD patients (AD, n =3) and Parkinson’s disease patients (PD, n = 3) were collected by standardized procedure and immediately frozen at –80°C. Samples underwent 5 freeze/thaw (–80°C/room temperature) cycles. The concentrations of Aβ1–40, Aβ1–42, and T-tau were monitored during the freeze/thaw tests using an immunomagnetic reduction (IMR) assay. The relative percentage of concentrations after every freeze/thaw cycle was calculated for each biomarker. Results: A tendency of decrease in the averaged relative percentages over samples through the freeze and thaw cycles for Aβ1–40 (100 to 97.11%), Aβ1–42 (100 to 94.99%), and T-tau (100 to 95.65%) was found. However, the decreases were less than 6%. For all three biomarkers, no statistical significance was found between the levels of fresh plasma and those of the plasma experiencing 5 freeze/thaw cycles (p > 0.1). Conclusions: Plasma Aβ1–40, Aβ1–42, and T-tau are stable through 5 freeze/thaw cycles measured with IMR.

scholarly journals P1-247: LONGITUDINAL VARIATIONS IN PLASMA AMYLOID-β 1-42 AND TOTAL TAU PROTEIN IN SUBJECTS WITH STABLE COGNITION

2019 ◽  
Vol 15 ◽  
pp. P333-P333
Author(s):  
Shieh-Yueh Yang ◽  
Pei-Ning Wang ◽  
Ming-Chyi Pai ◽  
C.P. Huang ◽  
Wen-Ping Chen
Keyword(s):  
Tau Protein ◽  
Amyloid Β ◽  
Total Tau ◽  
Longitudinal Variations

scholarly journals P2-223: STABILITY OF PLASMA AMYLOID-β 1-40, AMYLOID-β 1-42 AND TOTAL TAU OVER REPEATED FREEZE/THAW CYCLES

2019 ◽  
Vol 15 ◽  
pp. P663-P663
Author(s):  
H.C. Liu ◽  
Ming-Jang Chiu ◽  
Chin-Hsien Lin ◽  
Wen-Ping Chen ◽  
Shieh-Yueh Yang
Keyword(s):  
Amyloid Β ◽  
Freeze Thaw ◽  
Total Tau

Use of cerebrospinal fluid amyloid-β and total tau protein to predict favorable surgical outcomes in patients with idiopathic normal pressure hydrocephalus

2011 ◽  
Vol 115 (1) ◽  
pp. 145-150 ◽  
Author(s):  
Andrew Tarnaris ◽  
Ahmed. K. Toma ◽  
Miles D. Chapman ◽  
Geoff Keir ◽  
Neil D. Kitchen ◽  
...  
Keyword(s):  
Normal Pressure Hydrocephalus ◽  
Tau Protein ◽  
Surgical Outcomes ◽  
Amyloid Β ◽  
Normal Pressure ◽  
Idiopathic Normal Pressure Hydrocephalus ◽  
Favorable Outcome ◽  
Enzyme Linked Immunosorbent Assay ◽  
Total Tau

Object The prognostic value of CSF biomarkers in patients with idiopathic normal pressure hydrocephalus (iNPH) has not been adequately studied to date. The aim of this study was to identify CSF markers of favorable surgical outcome in patients with iNPH undergoing the insertion of a ventriculoperitoneal shunt. Methods Ventricular CSF was collected intraoperatively from 22 patients with iNPH and enzyme-linked immunosorbent assay was used to analyze the levels of amyloid-β 1–42 (Aβ1–42) and total tau protein. The Black grading scale was used to assess outcomes at 6 months. Receiver operating characteristic (ROC) curves were obtained and discriminant function analysis was undertaken to provide sensitivity and specificity figures for each marker as well as their combination. Results The mean age of the patients was 71.45 years (± 9.5 years [SD]). Follow-up was achieved in 21 patients. Seventeen patients had a favorable outcome and 4 patients had unfavorable outcome at 6 months. An Aβ1–42 level of 180 pg/ml had a sensitivity of 35% and a specificity of 20% for predicting a favorable outcome at 6 months. A total tau level of 767 pg/ml will have a sensitivity of 17% and a specificity of 20% for predicting a favorable outcome at 6 months. A combination of Aβ1–42 and total tau levels predicted favorable outcomes with a sensitivity of 80% and specificity of 82.4%. Conclusions In this pilot study a combination of Aβ1–42 levels and total tau protein levels predicted favorable surgical outcomes at 6 months with adequate accuracy to be of clinical use. Further study in a larger group with longer follow-up is warranted.

Increased levels of total tau protein in the cerebrospinal fluid in Huntington’s disease

2011 ◽  
Vol 17 (9) ◽  
pp. 714-715 ◽  
Author(s):  
Radu Constantinescu ◽  
Megan Romer ◽  
Henrik Zetterberg ◽  
Lars Rosengren ◽  
Karl Kieburtz
Keyword(s):  
Cerebrospinal Fluid ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Tau Protein ◽  
Total Tau

Age-Dependency of Total Tau in the Cerebrospinal Fluid Is Corrected by Amyloid-β 1–40: A Correlational Study in Healthy Adults

2021 ◽  
pp. 1-8
Author(s):  
Paul Theo Zebhauser ◽  
Achim Berthele ◽  
Marie-Sophie Franz ◽  
Oliver Goldhardt ◽  
Janine Diehl-Schmid ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Amyloid Β ◽  
Healthy Adults ◽  
Tau Proteins ◽  
Clinical Settings ◽  
Inclusion Criteria ◽  
Total Tau ◽  
Potential Marker ◽  
Wide Range ◽  
The Relationship

Background: Tau proteins are established biomarkers of neuroaxonal damage in a wide range of neurodegenerative conditions. Although measurement of total-Tau in the cerebrospinal fluid is widely used in research and clinical settings, the relationship between age and total-Tau in the cerebrospinal fluid is yet to be fully understood. While past studies reported a correlation between age and total-Tau in the cerebrospinal fluid of healthy adults, in clinical practice the same cut-off value is used independently of patient’s age. Objective: To further explore the relationship between age and total-Tau and to disentangle neurodegenerative from drainage-dependent effects. Methods: We analyzed cerebrospinal fluid samples of 76 carefully selected cognitively healthy adults and included amyloid-β 1–40 as a potential marker of drainage from the brain’s interstitial system. Results: We found a significant correlation of total-Tau and age, which was no longer present when correcting total-Tau for amyloid-β 1–40 concentrations. These findings were replicated under varied inclusion criteria. Conclusion: Results call into question the association of age and total-Tau in the cerebrospinal fluid. Furthermore, they suggest diagnostic utility of amyloid-β 1–40 as a possible proxy for drainage-mechanisms into the cerebrospinal fluid when interpreting biomarker concentrations for neurodegenerative diseases.

Immunotherapeutics for AD: A Work in Progress

2021 ◽  
Vol 20 ◽  
Author(s):  
Anuja Sharma ◽  
Jaspreet Singh Anand ◽  
Yatender Kumar
Keyword(s):  
Tau Protein ◽  
Therapeutic Strategy ◽  
Neurodegenerative Disorder ◽  
Disease Onset ◽  
Amyloid Β ◽  
Therapeutic Strategies ◽  
Genetic Defects ◽  
Multiple Factors ◽  
Neurodegenerative Process ◽  
Epigenetic Regulations

: Alzheimer's Disease (AD), often called the 'Plague of the 21st Century,' is a progressive, irreversible neurodegenerative disorder that leads to the degeneration and death of neurons. Multiple factors, such as genetic defects, epigenetic regulations, environmental factors, or cerebrovascular damage, are a manifestation of the neurodegenerative process that begins to occur decades before the onset of disease. To date, no treatment or therapeutic strategy has proven to be potent in inhibiting its progress or reversing the effects of the disease. The ever-increasing numbers and lack of sufficient therapies that can control or reverse the effects of the disease have propelled research in the direction of devising efficient therapeutic strategies for AD. This review comprehensively discusses the active and passive immunotherapies against Amyloid-β and Tau protein, which remain the popular choice of targets for AD therapeutics. Some of the prospective immunotherapies against Aβ plaques have failed due to various reasons. Much of the research is focused on targeting Tau, specifically, targeting the mid-region of extracellular Tau due to their potential to prevent seeding and hence the spread of neurofibrillary tangles (NFTs). Thus, there is a need to thoroughly understand the disease onset mechanisms and discover effective therapeutic strategies.

scholarly journals Effects of resveratrol and morin on insoluble tau in tau transgenic mice

2018 ◽  
Vol 9 (1) ◽  
pp. 54-60 ◽  
Author(s):  
Kwun Chung Yu ◽  
Ping Kwan ◽  
Stanley K.K. Cheung ◽  
Amy Ho ◽  
Larry Baum
Keyword(s):  
Transgenic Mice ◽  
Motor Function ◽  
Tau Protein ◽  
Late Stage ◽  
Animal Studies ◽  
Paired Helical Filaments ◽  
Hyperphosphorylated Tau ◽  
Total Tau ◽  
Tau Aggregation ◽  
Do So

Abstract Tauopathies are neurodegenerative diseases, including Alzheimer’s disease (AD) and frontotemporal dementia (FTD), in which tau protein aggregates within neurons. An effective treatment is lacking and is urgently needed. We evaluated two structurally similar natural compounds, morin and resveratrol, for treating tauopathy in JNPL3 P301L mutant human tau overexpressing mice. Rotarod tests were performed to determine effects on motor function. After treatment from age 11 to 14 months, brains of 26 mice were collected to quantify aggregated hyperphosphorylated tau by Thioflavin T and immunohistochemistry (IHC) and to quantify total tau (HT7 antibody) and hyperphosphorylated tau (AT8 antibody) in homogenates and a fraction enriched for paired helical filaments. Resveratrol reduced the level of total hyperphosphorylated tau in IHC sections (p=0.036), and morin exhibited a tendency to do so (p=0.29), while the two drugs tended to increase the proportion of solubilizable tau that was hyperphosphorylated, as detected in blots. Neither resveratrol nor morin affected motor function. One explanation of these results is that the drugs might interrupt a late stage in tau aggregation, after small aggregates have formed but before further aggregation has occurred. Further animal studies would be informative to explore the possible efficacy of morin or resveratrol for treating tauopathies.

A Numerical Study of Sensitivity Coefficients for a Model of Amyloid Precursor Protein and Tubulin-Associated Unit Protein Transport and Agglomeration in Neurons at the Onset of Alzheimer's Disease

2019 ◽  
Vol 141 (3) ◽  
Author(s):  
I. A. Kuznetsov ◽  
A. V. Kuznetsov
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Amyloid Precursor Protein ◽  
Tau Protein ◽  
Protein Transport ◽  
Numerical Study ◽  
Amyloid Β ◽  
Precursor Protein ◽  
Model Parameters ◽  
In The Beginning

Modeling of intracellular processes occurring during the development of Alzheimer's disease (AD) can be instrumental in understanding the disease and can potentially contribute to finding treatments for the disease. The model of intracellular processes in AD, which we previously developed, contains a large number of parameters. To distinguish between more important and less important parameters, we performed a local sensitivity analysis of this model around the values of parameters that give the best fit with published experimental results. We show that the influence of model parameters on the total concentrations of amyloid precursor protein (APP) and tubulin-associated unit (tau) protein in the axon is reciprocal to the influence of the same parameters on the average velocities of the same proteins during their transport in the axon. The results of our analysis also suggest that in the beginning of AD the aggregation of amyloid-β and misfolded tau protein have little effect on transport of APP and tau in the axon, which suggests that early damage in AD may be reversible.

scholarly journals Carboxy-Terminus Tau Protein Hyperphosphorylation is Associated with Extracellular Deposits of Amyloid-β Fibrillary in a Triple-Transgenic Model of Alzheimer’s Disease

2017 ◽  
Vol 05 (03) ◽  
Author(s):  
Miguel Angel Ontiveros Torres ◽  
Leonel Castellanos Aguilar ◽  
Jonathan Lennel Gutierrez Murcia ◽  
Nayeli Martinez Zuniga ◽  
Paola Flores Rodriguez ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Tau Protein ◽  
Amyloid Β ◽  
Carboxy Terminus ◽  
Transgenic Model ◽  
Model Of Alzheimer’S Disease
Sign in / Sign up

Export Citation Format

Share Document